One important characteristic of this market is the high rate of product switching, which facilitates the entry of new drugs. Soltara has not been partnered and Sepracor intends to market and sell the product through its own sales force. It appears the market has finally bottomed out, since the volume of shares trading is up, and money is flowing out of treasuries and back into stocks. These are indications that investors rather put their money into growth, and Sepracor is one company that is poised for growth. Such Information is neither an offer to sell nor a solicitation to buy the securities of any company.
Additional information is available upon request.
Information in this publication has been obtained from sources believed to be reliable, but the accuracy, completeness and interpretation are not guaranteed. Opinions expressed are subject to change without notice. The Information is supplied on the condition that the reader or any other person receiving the Information will make his or her own determination as to its suitability for any purpose prior to any use of the Information. This report may not be reproduced, distributed or published by any recipient for any purpose without the prior express consent of the publishers. Changes in rates of currency exchange may have an adverse effect on the value, price or income of investments.